Clinical Care Options Oncology - Colorectal Cancer http://clinicaloptions.com/Oncology.aspx New treatment data and educational activities for Oncology and Hematology Clinicians en-us Clinical Care Options Oncology - Colorectal Cancer http://images.imedoptions.com/img.asp?img=cco/CCO_ONC_RSS.gif http://clinicaloptions.com/oncology Master Class in Management of Liver Metastases From Colorectal Cancer: Case-Based Learninghttp://clinicaloptions.com/Oncology/Treatment%20Updates/Liver%20Metastases%20Master%20Class/Virtual%20Presentation/Master%20Class%20Virtual%20Presentation.aspxSteven R. Alberts, MD, reviews recent data on current and novel therapeutic approaches for managing liver metastases in patients with colorectal cancer and examines how this knowledge is applied in practice in 3 patient cases. Conference Report From the 2008 Gastrointestinal Cancers Symposium: Colorectal Cancershttp://clinicaloptions.com/Oncology/Conference%20Coverage/GI%202008/Tracks/Colorectal%20Cancers/Colorectal%20Cancers.aspxAlan P. Venook, MD, and Richard M. Goldberg, MD, discuss results presented at the 2008 Gastrointestinal Cancers Symposium regarding current therapy for colorectal cancers. Exploring Biomarkers and Surrogates in Optimizing Patient Outcomeshttp://clinicaloptions.com/Oncology/Treatment%20Updates/mCRC%20Advances/Virtual%20Presentations/Van%20Cutsem.aspxEric Van Cutsem, MD, PhD, discusses the emerging use of biomarkers in the clinical management of patients with metastatic colorectal cancer. Controversies in Care: Using Clinical Data to Guide Treatment Selectionhttp://clinicaloptions.com/Oncology/Treatment%20Updates/mCRC%20Advances/Virtual%20Presentations/Eng.aspxCathy Eng, MD, reviews recent data regarding the use of clinical data to optimize treatment of colorectal cancer. Potentially Curable Metastatic Disease in Colorectal Cancer: Neoadjuvant Approach to Liver-Limited Diseasehttp://clinicaloptions.com/Oncology/Treatment%20Updates/mCRC%20Advances/Virtual%20Presentations/Chu.aspxEdward Chu, MD, reviews neoadjuvant strategies to improve outcomes in patients with liver-limited metastatic colorectal cancer. Update on the Science of Current Therapy for Metastatic Colorectal Cancerhttp://clinicaloptions.com/Oncology/Treatment%20Updates/mCRC%20Advances/Virtual%20Presentations/Hecht.aspxJ. Randolph Hecht, MD, reviews current therapeutic options for metastatic colorectal cancer. Update on the Use of Oral Therapies in Colon and Rectal Cancers http://clinicaloptions.com/Oncology/Treatment%20Updates/CRC%20-%20Oral%20Therapy/Modules/Treatment%20Update.aspx David H. Ilson, MD, PhD, describes recent data on treatment approaches using oral agents in the management of colon and rectal cancers. Case: Management of a 65-Year-Old Male With Metastatic Colorectal Cancer and Gilbert's Syndrome http://clinicaloptions.com/Oncology/Treatment%20Updates/CRC%20-%20Oral%20Therapy/Interactive%20Case%20Challenges/Metastatic%20Colorectal.aspx Alan P. Venook, MD reviews options for cytotoxic and targeted agents as first-line treatment of a patient with metastatic colorectal cancer and Gilberts syndrome. Advanced Colorectal Cancer and Novel Therapies http://clinicaloptions.com/Oncology/Management%20Series/GI%20Cancer/Modules/Novel.aspx Daniel G. Haller, MD, reviews the current treatment of advanced colorectal cancer and discusses emerging therapies. Colorectal Cancer Detection and Diagnosis http://clinicaloptions.com/Oncology/Management%20Series/GI%20Cancer/Modules/Detection.aspx Heinz-Josef Lenz, MD, reviews modalities for the detection and imaging of colorectal cancer. Adjuvant Treatment for Colon Cancer http://clinicaloptions.com/Oncology/Management%20Series/GI%20Cancer/Modules/Colon.aspx Richard M. Goldberg, MD, reviews the current use of adjuvant chemotherapy for patients with colon cancer. Colorectal Cancer Prevention http://clinicaloptions.com/Oncology/Management%20Series/GI%20Cancer/Modules/Prevention.aspx Axel Grothey, MD, reviews strategies to decrease the risk of colorectal cancer. Adjuvant Treatment for Rectal Cancer http://clinicaloptions.com/Oncology/Management%20Series/GI%20Cancer/Modules/Rectal.aspx Joel E. Tepper, MD, reviews the current use of adjuvant chemotherapy for patients with rectal cancer Colorectal Cancer: Demographics and Screening http://clinicaloptions.com/Oncology/Management%20Series/GI%20Cancer/Modules/Screening.aspx Dennis J. Ahnen, MD, reviews current and emerging screening techniques for colorectal cancer. Expert Analysis: Gastrointestinal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Gastrointestinal%20Cancer.aspx Axel Grothey, MD, John L. Marshall, MD, and Alan P. Venook, MD, review data from the meeting in Chicago. EGFR, HER2, and K-RAS Biomarkers Predict Response to Cetuximab in Colorectal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4021.aspx Results of a retrospective analysis of biomarkers in metastatic colorectal cancer suggested that a combination of EGFR copy number and K-ras mutational status may improve prediction of response to cetuximab therapy. Adding Cetuximab to Irinotecan May Improve Quality of Life vs Irinotecan Alone in Patients With Metastatic Colorectal Cancer (EPIC Trial) http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4003.aspx Results of the phase III EPIC trial demonstrate improvements in quality of life when cetuximab is added to irinotecan in patients with metastatic colorectal cancer who previously failed treatment with oxaliplatin-based therapy. Sorafenib Prolongs Survival in Advanced Hepatocellular Carcinoma http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/LBA1.aspx In a phase III trial, sorafenib was associated with a 44% increase in overall survival and a 73% increase in time to progression for patients with advanced HCC. Cetuximab Added to FOLFIRI Significantly Improves Progression-Free Survival in Previously Untreated Patients With Metastatic Colorectal Cancer (CRYSTAL Study) http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4000.aspx Results of the phase III CRYSTAL trial show that first-line combination treatment with cetuximab and FOLFIRI is well tolerated and significantly improved clinical outcomes vs FOLFIRI alone in patients with metastatic colorectal cancer. Phase III MOSAIC 6-Year Follow-up Data Confirm Survival Benefit for Adjuvant FOLFOX4 in Stage III Colon Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4007.aspx In final 6-year follow-up, FOLFOX4 improved disease-free and overall survival for patients with stage III colon cancer. Phase III Results Suggest S-1 as Possible Standard Chemotherapy for Advanced Gastric Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4513.aspx S-1 was shown to be noninferior to 5-FU in a phase III study of patients with unresectable or recurrent gastric cancer. Perioperative FOLFOX4 Increases PFS in Metastatic Colorectal Cancer With Resectable Liver Metastases http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/LBA5.aspx Results of the EORTC 40983 phase III study show that perioperative FOLFOX4 therapy improved PFS in patients with colorectal cancer with resectable liver metastases compared with surgery alone. Extending First-Line Bevacizumab Treatment Past First Disease Progression May Improve Survival Outcomes for Patients With Metastatic Colorectal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4036.aspx In an exploratory analysis of the BRiTE registry, patients with metastatic colorectal cancer treated with bevacizumab beyond first progression appear to have longer overall and median survival compared with patients who do not receive postprogression bevacizumab. Circulating Tumor Cell Number Predicts Survival in Metastatic Colorectal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4010.aspx Results of a multicenter international study show that circulating tumor cells are a significant independent positive prognostic factor for survival in patients with metastatic colorectal cancer. Increased Progression-Free and Overall Survival Observed With FOLFIRI With or Without Bevacizumab Compared With Modified-Bolus IFL and CapeIri in Patients With Previously Untreated Metastatic Colorectal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4027.aspx Updated BICC-C results demonstrate that FOLFIRI without bevacizumab produced significantly better progression-free survival than modified-bolus IFL or CapeIri and better overall survival than modified-bolus IFL when combined with bevacizumab in metastatic colorectal cancer. Bevacizumab Added to Oxaliplatin- and Fluoropyrimidine-Based Chemotherapy May Improve Survival in First-Line Treatment of Metastatic Colorectal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4028.aspx Addition of bevacizumab to oxaliplatin-based chemotherapy prolonged progression-free survival and showed a trend toward improved overall survival in patients with previously untreated metastatic colorectal cancer. Ratio of Positive-to-Examined Lymph Nodes Predicts Overall Survival in Patients With Resected Node-Positive Rectal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4006.aspx A retrospective analysis of INT 0114 shows lymph node ratio (proportion of positive to total examined) predicts survival in patients with resected node-positive rectal cancer. "Western" Diets Associated With Poor Outcomes for Patients With Established, Treated Stage III Colon Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4019.aspx In a prospective, observational study of patients treatmed for stage III colon cancer, a "Western" diet is associated with worse progression-free, recurrence-free, and overall survival compared with a more "prudent" diet (eg, high intake of fruit, vegetables, poultry, and fish). Chemotherapy-Free Interval Not Recommended Following Oxaliplatin-Based Chemotherapy in Treatment of Metastatic Colorectal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4013.aspx Final results of OPTIMOX2 phase II study do not support the introduction of a chemotherapy-free interval (CFI) following FOLFOX7 chemotherapy in patients with metastatic colorectal cancer CALGB 80303: Addition of Bevacizumab to Gemcitabine Confers No Survival Advantage in Advanced Pancreatic Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4508.aspx Results of the phase III CALGB 80303 study of patients with advanced pancreatic cancer showed bevacizumab plus gemcitabine increased the rate of hypertension and proteinuria and did not significantly improve survival or response vs gemcitabine plus placebo Sequential Compared to Combination Chemotherapy With Capecitabine, Irinotecan, and Oxaliplatin in Advanced Colorectal Cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) Phase III Study http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4012.aspx Median overall survival was not prolonged with the combined use of cytotoxic drugs (capecitabine, irinotecan, oxaliplatin) compared with sequential therapy in patients with advanced colorectal cancer. Preoperative Treatment With 5-Fluorouracil Plus Cisplatin Significantly Improved Survival Outcomes in Resectable Adenocarcinoma of Stomach and Lower Esophagus http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/4510.aspx Results of the randomized ACCORD 07 trial show that, compared with surgery alone, preoperative 5-FU plus cisplatin offers significant improvements in rates of curative resection, OS, and DFS, with no increase in morbidity